Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis.

Chegou NN, Sutherland JS, Namuganga AR, Corstjens PL, Geluk A, Gebremichael G, Mendy J, Malherbe S, Stanley K, van der Spuy GD, Kriel M, Loxton AG, Kriel B, Simukonda F, Bekele Y, Sheehama JA, Nelongo J, van der Vyver M, Gebrexabher A, Hailu H, Esterhuyse MM, Rosenkrands I, Aagard C, Kidd M, Kassa D, Mihret A, Howe R, Cliff JM, Crampin AC, Mayanja-Kizza H, Kaufmann SHE, Dockrell HM, Ottenhoff THM, Walzl G; AE-TBC consortium.

Sci Rep. 2018 Feb 8;8(1):2675. doi: 10.1038/s41598-018-20855-7.

2.

Prospective evaluation of host biomarkers other than interferon gamma in QuantiFERON Plus supernatants as candidates for the diagnosis of tuberculosis in symptomatic individuals.

Manngo PM, Gutschmidt A, Snyders CI, Mutavhatsindi H, Manyelo CM, Makhoba NS, Ahlers P, Hiemstra A, Stanley K, McAnda S, Kidd M, Malherbe ST, Walzl G, Chegou NN.

J Infect. 2019 Sep;79(3):228-235. doi: 10.1016/j.jinf.2019.07.007. Epub 2019 Jul 15.

3.

Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB.

Chegou NN, Sutherland JS, Malherbe S, Crampin AC, Corstjens PL, Geluk A, Mayanja-Kizza H, Loxton AG, van der Spuy G, Stanley K, Kotzé LA, van der Vyver M, Rosenkrands I, Kidd M, van Helden PD, Dockrell HM, Ottenhoff TH, Kaufmann SH, Walzl G; AE-TBC consortium.

Thorax. 2016 Sep;71(9):785-94. doi: 10.1136/thoraxjnl-2015-207999. Epub 2016 May 4.

4.

Host biomarkers detected in saliva show promise as markers for the diagnosis of pulmonary tuberculosis disease and monitoring of the response to tuberculosis treatment.

Jacobs R, Tshehla E, Malherbe S, Kriel M, Loxton AG, Stanley K, van der Spuy G, Walzl G, Chegou NN.

Cytokine. 2016 May;81:50-6. doi: 10.1016/j.cyto.2016.02.004. Epub 2016 Feb 13.

PMID:
26878648
5.

Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report.

Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G.

BMC Pulm Med. 2009 May 16;9:21. doi: 10.1186/1471-2466-9-21.

6.

Biomarkers for discrimination between latent tuberculosis infection and active tuberculosis disease.

Won EJ, Choi JH, Cho YN, Jin HM, Kee HJ, Park YW, Kwon YS, Kee SJ.

J Infect. 2017 Mar;74(3):281-293. doi: 10.1016/j.jinf.2016.11.010. Epub 2016 Nov 19.

PMID:
27871809
7.

Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response.

Jacobs R, Maasdorp E, Malherbe S, Loxton AG, Stanley K, van der Spuy G, Walzl G, Chegou NN.

PLoS One. 2016 Aug 3;11(8):e0160546. doi: 10.1371/journal.pone.0160546. eCollection 2016.

8.

Host cytokine responses induced after overnight stimulation with novel M. tuberculosis infection phase-dependent antigens show promise as diagnostic candidates for TB disease.

Essone PN, Chegou NN, Loxton AG, Stanley K, Kriel M, van der Spuy G, Franken KL, Ottenhoff TH, Walzl G.

PLoS One. 2014 Jul 15;9(7):e102584. doi: 10.1371/journal.pone.0102584. eCollection 2014.

9.

Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects.

Hur YG, Kang YA, Jang SH, Hong JY, Kim A, Lee SA, Kim Y, Cho SN.

J Infect. 2015 Apr;70(4):346-55. doi: 10.1016/j.jinf.2014.10.019. Epub 2014 Nov 5.

10.

Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response.

Jacobs R, Malherbe S, Loxton AG, Stanley K, van der Spuy G, Walzl G, Chegou NN.

Oncotarget. 2016 Sep 6;7(36):57581-57592. doi: 10.18632/oncotarget.11420.

11.

Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease.

Awoniyi DO, Teuchert A, Sutherland JS, Mayanja-Kizza H, Howe R, Mihret A, Loxton AG, Sheehama J, Kassa D, Crampin AC, Dockrell HM, Kidd M, Rosenkrands I, Geluk A, Ottenhoff TH, Corstjens PL, Chegou NN, Walzl G; AE-TBC Consortium.

J Infect. 2016 Sep;73(3):219-30. doi: 10.1016/j.jinf.2016.04.036. Epub 2016 Jun 14.

12.

Screening and identification of a six-cytokine biosignature for detecting TB infection and discriminating active from latent TB.

Wang S, Li Y, Shen Y, Wu J, Gao Y, Zhang S, Shao L, Jin J, Zhang Y, Zhang W.

J Transl Med. 2018 Jul 20;16(1):206. doi: 10.1186/s12967-018-1572-x.

13.

In vitro QuantiFERON-TB gold antigen specific interleukin-1beta to diagnose TB among HIV-positive subjects.

Prabhavathi M, Ahamed Kabeer BS, Deenadayalan A, Raja A.

Tuberculosis (Edinb). 2016 Jan;96:27-30. doi: 10.1016/j.tube.2015.10.005. Epub 2015 Nov 10.

PMID:
26786651
14.

Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.

Wyndham-Thomas C, Dirix V, Schepers K, Martin C, Hildebrand M, Goffard JC, Domont F, Libin M, Loyens M, Locht C, Van Vooren JP, Mascart F.

BMC Infect Dis. 2015 Feb 14;15:59. doi: 10.1186/s12879-015-0796-0.

15.

Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV.

Farr K, Ravindran R, Strnad L, Chang E, Chaisson LH, Yoon C, Worodria W, Andama A, Ayakaka I, Bbosa Nalwanga P, Byanyima P, Kalema N, Kaswabuli S, Katagira W, Aman KD, Musisi E, Tumwine NW, Sanyu I, Ssebunya R, Davis JL, Huang L, Khan IH, Cattamanchi A.

PLoS One. 2018 Oct 23;13(10):e0206119. doi: 10.1371/journal.pone.0206119. eCollection 2018.

16.

Cytokine and chemokine expression profiles in response to Mycobacterium tuberculosis stimulation are altered in HIV-infected compared to HIV-uninfected subjects with active tuberculosis.

Waruk JL, Machuki Z, Mesa C, Juno JA, Anzala O, Sharma M, Ball TB, Oyugi J, Kiazyk S.

Tuberculosis (Edinb). 2015 Sep;95(5):555-61. doi: 10.1016/j.tube.2015.05.001. Epub 2015 May 22.

PMID:
26073895
17.

Evaluation of a whole-blood chemiluminescent immunoassay of IFN-γ, IP-10, and MCP-1 for diagnosis of active pulmonary tuberculosis and tuberculous pleurisy patients.

Liang Y, Wang Y, Li H, Yang Y, Liu J, Yu T, Wu X.

APMIS. 2016 Oct;124(10):856-64. doi: 10.1111/apm.12583. Epub 2016 Aug 15.

PMID:
27523388
18.

Diagnostic performance of GM-CSF and IL-2 in response to long-term specific-antigen cell stimulation in patients with active and latent tuberculosis infection.

Balcells ME, Ruiz-Tagle C, Tiznado C, García P, Naves R.

Tuberculosis (Edinb). 2018 Sep;112:110-119. doi: 10.1016/j.tube.2018.08.006. Epub 2018 Aug 13.

PMID:
30205963
19.

Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting.

Chegou NN, Detjen AK, Thiart L, Walters E, Mandalakas AM, Hesseling AC, Walzl G.

PLoS One. 2013 May 15;8(5):e64226. doi: 10.1371/journal.pone.0064226. Print 2013.

20.

Evaluation of IL-2, IL-10, IL-17 and IP-10 as potent discriminative markers for active tuberculosis among pulmonary tuberculosis suspects.

You E, Kim MH, Lee WI, Kang SY.

Tuberculosis (Edinb). 2016 Jul;99:100-8. doi: 10.1016/j.tube.2016.04.009. Epub 2016 Apr 28.

PMID:
27450011

Supplemental Content

Support Center